Short answer: Some do, for the people studied. Ozempic, Victoza, Trulicity and Mounjaro are approved to lower the risk of heart attack, stroke and heart-related death in adults with type 2 diabetes and heart disease or high risk, and Wegovy in adults with heart disease and overweight or obesity. In the placebo-controlled trials, the risk of a first major heart event was 12% to 26% lower. Zepbound has no heart-risk approval.
Each of these labels (section 1) lists reducing the risk of "major adverse cardiovascular events", meaning heart-related death, a heart attack that is not fatal or a stroke that is not fatal. The approval is narrower than "everyone on a GLP-1": it names who was studied.
| Medicine | Approved to lower heart-event risk in | Trial |
|---|---|---|
| Wegovy (semaglutide) | Adults with established heart disease and obesity or overweight | SELECT (Study 1) |
| Ozempic (semaglutide) | Adults with type 2 diabetes and established heart disease | SUSTAIN 6 |
| Victoza (liraglutide) | Adults with type 2 diabetes and established heart disease | LEADER |
| Trulicity (dulaglutide) | Adults with type 2 diabetes and heart disease or several risk factors | REWIND |
| Mounjaro (tirzepatide) | Adults with type 2 diabetes at high risk of these events | SURPASS-CVOT |
| Zepbound (tirzepatide) | No heart-risk approval; approved for weight and for sleep apnea | None listed |
| Trial | People and follow-up | Medicine vs comparison | Hazard ratio |
|---|---|---|---|
| SELECT (Wegovy 2.4 mg) | 17,604 adults 45+ without diabetes; median 41.8 months | 6.5% vs 8% on placebo | 0.80 |
| SUSTAIN 6 (Ozempic) | 3,297 adults with type 2 diabetes; median 2.1 years | 6.6% vs 8.9% on placebo | 0.74 |
| LEADER (Victoza) | 9,340 adults with type 2 diabetes; median 3.5 years | 13.0% vs 14.9% on placebo | 0.87 |
| REWIND (Trulicity 1.5 mg) | 9,901 adults with type 2 diabetes; median 5.4 years | Rates not in label text | 0.88 |
| SURPASS-CVOT (Mounjaro) | 13,299 adults with type 2 diabetes; median 210.1 weeks | 12.1% vs 13.0% on dulaglutide | 0.92 |
A hazard ratio of 0.80 means the risk of a first event was about 20% lower over the trial (see hazard ratio). The absolute gaps are smaller: in SELECT, 569 of 8,803 people on Wegovy had an event against 701 of 8,801 on placebo.
SURPASS-CVOT is different: it compared Mounjaro with Trulicity, which already lowers heart risk. The label says Mounjaro was non-inferior, and that superiority to dulaglutide was not established.
The labels break the combined outcome into pieces but warn against reading too much into them. In SELECT, fatal or non-fatal heart attack was 2.8% on Wegovy and 3.8% on placebo, but that line sat outside the planned statistical testing. Heart-related death (2.5% vs 3%) did not reach the bar for a proven difference, and the label adds that an effect on heart failure has not been established.
In SUSTAIN 6, non-fatal stroke was 1.6% on Ozempic and 2.7% on placebo. In LEADER, all-cause death was lower with Victoza (hazard ratio 0.85). In REWIND, 10.8% of people on Trulicity died during the trial against 12.0% on placebo.
These results come from people who already had heart disease, or diabetes with high heart risk, and who stayed on usual heart care such as statins and blood pressure medicines. SELECT excluded anyone with diabetes. The labels do not show the same result for people without those conditions, and the Zepbound label has no heart-outcome trial in section 14.
Whether a GLP-1 fits a heart-risk plan is a question for the prescriber. Dose Track keeps each weekly dose on a log, along with weight and notes, so the history is easy to bring to that visit.
Read more on Dose Track: Wegovy dosing guide · Ozempic dosing guide · Hazard ratio · Relative vs absolute risk